Trial Profile
A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX (100 µg, 200 µg, 400 µg b.i.d. for 14 Days ) in Healthy Male Volunteers (Randomised, Double-blind Within Each Dose Group, Placebo-controlled, Parallel-group)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Aug 2014
Price :
$35
*
At a glance
- Drugs Sarakalim (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Aug 2014 New trial record